Buy Cipla; target of Rs 940: Dolat Capital Market

Dolat Capital Market is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 940 in its research report dated January 31, 2021.

Buy Cipla; target of Rs 950: Sharekhan

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 950 in its research report dated January 29, 2021.

Accumulate Cipla; target of Rs 913: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Cipla with a target price of Rs 913 in its research report dated February 01, 2021.

Buy Cipla; target of Rs 975: ICICI Direct

ICICI Direct is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 975 in its research report dated January 30, 2021.

Lupin: New launches and market share gains are likely to override pricing erosion

New launches in the US, particularly in the inhalation category, and an improving market share are expected to help ride over structural pricing erosion in the near term for Lupin

Neutral Cipla; target of Rs 900: Motilal Oswal

Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 900 in its research report dated January 30, 2021.

Buy Cipla; target of Rs 1020: HDFC Securities

HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1020 in its research report dated February 01, 2021.

Cipla Consolidated December 2020 Net Sales at Rs 5,168.69 crore, up 18.25% Y-o-Y

Cipla Standalone December 2020 Net Sales at Rs 3,731.55 crore, up 27.52% Y-o-Y

Pharma: Ignore the noise as the core allocation is incremental

Focus on creating health infrastructure in the Budget 2021 is clearly an incrementally structural move which should indirectly benefit all the domestic oriented companies

Cipla — Large part of COVID opportunity has played out

In the US market, Albuterol opportunity remains a key lever for Cipla at least till the time Perrigo re-enters although in terms of market share, the drugmaker may be close to maturity

Cipla posts strong Q3 numbers, profit more than doubles to Rs 748.15 crore

The company's revenue for the quarter came at Rs 5,168.7 crore, up 18.2 percent from Rs 4,371 crore in the year-ago quarter.

Cipla Q3 PAT seen up 74.3% YoY to Rs. 612 cr: Yash Securities

Net Sales are expected to increase by 14 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs. 4985 crore, according to Yash Securities.

Cipla Q3 PAT seen up 77.2% YoY to Rs. 351 cr: Prabhudas Lilladher

Net Sales are expected to increase by 15.3 percent Y-o-Y (down 1.8 percent Q-o-Q) to Rs. 4,234.6 crore, according to Prabhudas Lilladher.

Cipla Q3 PAT seen up 73.2% YoY to Rs. 608.1 cr: ICICI Direct

Net Sales are expected to increase by 15.7 percent Y-o-Y (up 0.4 percent Q-o-Q) to Rs. 5,057.6 crore, according to ICICI Direct.

Will normalcy return to COVID-hit Indian pharmaceutical market in 2021?

The pharmaceutical sector is expecting sales to normalise by the second half of 2021, with the availability of COVID-19 vaccine and coronavirus receding.

Quant Pick - Cipla: ICICI Direct

According to ICICI Direct, Buy Cipla in range of Rs 790-807 Target: Rs 930 Stop Loss: Rs 725 Time frame: Three months.

Cipla share price gains on launching rapid antigen detection test

The company will commence the supply of rapid antigen test kits for COVID-19 in India from this week.

Buy Cipla; target of Rs 940: HDFC Securities

HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 940 in its research report dated December 14, 2020.

Buy Cipla; target of Rs 887: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 887 in its research report dated December 14, 2020.

Cipla share price jumps 5% after settlement with Celgene Corp

Nomura has maintained buy rating with a target at Rs 861 per share.

Hold Cipla; target of Rs 836: Prabhudas Lilladher

Prabhudas Lilladher recommended Hold rating on Cipla with a target price of Rs 836 in its research report dated November 09, 2020.

Buy Cipla: target of Rs 950: Sharekhan

Sharekhan is bullish on Cipla recommended buy rating on the stock with a target price of Rs 950 in its research report dated November 06, 2020.

Indian demand for COVID-19 drug Remdesivir rising sharply: Cipla

Remdesivir was developed by US drugmaker Gilead Sciences Inc , which cut its 2020 revenue forecast last month, citing lower-than-expected demand and difficulty in predicting sales of the treatment. Cipla is among several firms licensed to make and sell generic versions in developing nations.

Buy Cipla; target of Rs 942: Dolat Capital Market

Dolat Capital Market is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 942 in its research report dated November 07, 2020.